Long-term alpha-interferon therapy in myelodysplastic syndromes

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Myelodysplastic syndromes (MDS) carry a high risk of leukemic transformation and life-threatening complications.
• Current therapeutic options for MDS are limited, with no universally accepted treatment established.
• Previous studies indicated potential benefits of alpha-interferon (IFN-alpha) in MDS.

Purpose of the Study:

• To evaluate the efficacy and safety of long-term, high-dose IFN-alpha therapy in patients with low-risk MDS.
• To assess the impact of IFN-alpha on hematological parameters, disease progression, and clinical events in MDS.

Main Methods:

• A study involving ten patients diagnosed with low-risk MDS.
• Eight patients received prolonged treatment with IFN-alpha for 6-36 months.
• Dosages of IFN-alpha were adjusted over time (median 9, 6, 4 mU/week for years 1, 2, 3).
• Treatment response was assessed via peripheral blood and bone marrow analysis.

Main Results:

• A response rate of 30% (3 out of 10 patients) was observed after prolonged IFN-alpha exposure.
• One additional patient experienced retarded disease progression during the third year of therapy.
• Significant reductions in the incidence of infections and bleeding episodes were noted.
• Hematological and clinical parameters deteriorated rapidly in some patients upon IFN-alpha withdrawal.

Conclusions:

• Long-term, high-dose IFN-alpha therapy demonstrates a notable response rate in low-risk MDS.
• IFN-alpha treatment appears to improve patient susceptibility to infections, potentially prolonging survival.
• Further clinical trials are warranted to confirm the therapeutic role of IFN-alpha in MDS management.